DE3523021A1 - Verwendung von gangliosiden zur schmerzbehandlung - Google Patents

Verwendung von gangliosiden zur schmerzbehandlung

Info

Publication number
DE3523021A1
DE3523021A1 DE19853523021 DE3523021A DE3523021A1 DE 3523021 A1 DE3523021 A1 DE 3523021A1 DE 19853523021 DE19853523021 DE 19853523021 DE 3523021 A DE3523021 A DE 3523021A DE 3523021 A1 DE3523021 A1 DE 3523021A1
Authority
DE
Germany
Prior art keywords
gangliosides
ganglioside
mixture
weight
pharmaceutical agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19853523021
Other languages
German (de)
English (en)
Inventor
Silvana Padua/Padova Lorenzi
Aurelio Rom/Roma Romeo
Francesco Della Valle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SpA
Original Assignee
Fidia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia SpA filed Critical Fidia SpA
Publication of DE3523021A1 publication Critical patent/DE3523021A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE19853523021 1984-07-03 1985-06-27 Verwendung von gangliosiden zur schmerzbehandlung Ceased DE3523021A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48491/84A IT1177863B (it) 1984-07-03 1984-07-03 Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche

Publications (1)

Publication Number Publication Date
DE3523021A1 true DE3523021A1 (de) 1986-01-09

Family

ID=11266882

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19853523021 Ceased DE3523021A1 (de) 1984-07-03 1985-06-27 Verwendung von gangliosiden zur schmerzbehandlung

Country Status (11)

Country Link
US (1) US4707469A (enExample)
EP (1) EP0183572B1 (enExample)
JP (1) JPS6130521A (enExample)
AT (1) ATE78171T1 (enExample)
AU (1) AU582757B2 (enExample)
BE (1) BE902753A (enExample)
DE (1) DE3523021A1 (enExample)
GR (1) GR851572B (enExample)
IT (1) IT1177863B (enExample)
LU (1) LU85974A1 (enExample)
ZA (1) ZA854865B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463614A3 (en) * 1990-06-29 1992-07-01 Fidia S.P.A. The use of the gm1 monosialoganglioside and of its internal ester derivative to prevent the insurgence in man of the tolerance to the analgesic effect of morphine and analogues
WO1992020695A1 (en) * 1991-05-16 1992-11-26 Fidia S.P.A. Method for the preparation and purification of a mixture of glycosphingolipids free from contamination by non-conventional viruses

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) * 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
AU594468B2 (en) * 1986-05-12 1990-03-08 Mect Corporation Sialosylcholesterol, process for its preparation, and drug for treating diseases of nervous system
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
IT1212041B (it) * 1987-11-02 1989-11-08 Fidia Farmaceutici Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
NZ236059A (en) * 1989-11-17 1993-03-26 Fidia Spa Extraction of gangliosides
EP1349567A4 (en) * 2000-12-08 2005-10-12 Childrens Memorial Hospital COMPOSITIONS WITH GANGLIOSIDES FOR USE IN THE TREATMENT OF SKIN DISEASES
JP2005527467A (ja) 2001-08-29 2005-09-15 ネオーズ テクノロジーズ， インコーポレイテッド 新規な合成ガングリオシド誘導体およびその組成物
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
CA2518171C (en) 2003-03-06 2013-07-09 Neose Technologies, Inc. Methods and compositions for the enzymatic synthesis of gangliosides
US20050112183A1 (en) * 2003-11-25 2005-05-26 Galer Bradley S. Compositions and methods for treating neuropathic sensory loss
WO2010111530A1 (en) 2009-03-25 2010-09-30 Seneb Biosciences, Inc. Glycolipids as treatment for disease
US9609888B2 (en) 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
US10709770B2 (en) 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US10617701B2 (en) 2015-07-10 2020-04-14 Mead Johnson Nutrition Company Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
US10582714B2 (en) 2015-07-10 2020-03-10 Mead Johnson Nutrition Company Nutritional compositions and methods for promoting cognitive development
CN111407768A (zh) * 2020-05-15 2020-07-14 内蒙古自治区中医药研究所 一类组合物在神经损伤保护领域的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1046051B (it) * 1975-08-13 1980-06-30 Fidia Spa Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione
IT1212896B (it) * 1983-11-08 1989-11-30 Della Valle Francesco Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463614A3 (en) * 1990-06-29 1992-07-01 Fidia S.P.A. The use of the gm1 monosialoganglioside and of its internal ester derivative to prevent the insurgence in man of the tolerance to the analgesic effect of morphine and analogues
WO1992020695A1 (en) * 1991-05-16 1992-11-26 Fidia S.P.A. Method for the preparation and purification of a mixture of glycosphingolipids free from contamination by non-conventional viruses

Also Published As

Publication number Publication date
BE902753A (nl) 1985-12-30
IT8448491A1 (it) 1986-01-03
EP0183572A3 (en) 1987-07-22
ATE78171T1 (de) 1992-08-15
EP0183572A2 (en) 1986-06-04
IT8448491A0 (it) 1984-07-03
GR851572B (enExample) 1985-11-25
EP0183572B1 (en) 1992-07-15
LU85974A1 (fr) 1986-01-22
ZA854865B (en) 1987-09-30
AU582757B2 (en) 1989-04-13
AU4420785A (en) 1986-01-02
JPS6130521A (ja) 1986-02-12
US4707469A (en) 1987-11-17
IT1177863B (it) 1987-08-26

Similar Documents

Publication Publication Date Title
DE69818242T2 (de) Zusammensetzungen, enthaltend eine kombination aus freier sphingoid-base und ceramide sowie deren verwendung
US4707469A (en) Gangliosides mixture, useful as a therapeutical tool for eliminating painful effects or peripheral neuropathies
DE68928920T2 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE60034898T2 (de) Antiallergische Zusammensetzung, die OLIGOSACCHARIDe und eine Saponine oder eine basische Aminosäure enthält, zur topischen Verabreichung oder Inhalation
DE60215530T2 (de) Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält
EP2563370B1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
DE69106110T2 (de) Kosmetische Verwendung eines Mittels gegen Erytheme.
DE69019388T2 (de) Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor.
DE3519095A1 (de) Verwendung von gm(pfeil abwaerts)1(pfeil abwaerts) oder eines davon abgeleiteten inneren esters zur therapie von gehirnschlaegen
DE60126416T2 (de) Behandlung von arthritis und entsprechende zusammensetzungen
DE2549680A1 (de) Arzneimittel zur behandlung von ueberleitungsstoerungen des zentralen und peripheren nervensystems
DE69531546T2 (de) Synthetische gangliosid-derivate
DE69019122T2 (de) Stabilisierung und Wartung der biologischen Aktivität des Nervenwachstumsfaktor unter Benützung von natürlichen Gangliosiden oder deren Derivaten.
DE69218222T2 (de) Neue ganglioside-derivaten
DE68910275T2 (de) Arzneimittel und Methode zur Steigerung der mikrozirkulätorischen Durchfluss-Rate sowie des Volumens in den Kapillargefässen der Haut.
DE3721562A1 (de) Verwendung exogener ganglioside als schutzfaktor bei tumorerkrankungen
US5190925A (en) Use of gangliosides in the treatment of autonomic dysfunction in Chagas' disease
DE3829899C2 (de) Glyceringlycophosphatide und diese enthaltende pharmazeutische Mittel zur Bekämpfung von Hauterkrankungen
DE3883979T2 (de) Zusammensetzung auf der basis von cyclopolygalakturonsäure und verwendung derselben.
DE602004006024T2 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
DE1668171A1 (de) Verfahren zur herstellung von stabilen waessrigen loesungen neuer komplexer organosiliciumverbindungen
DE60213794T2 (de) Hautpräparat
DE69224303T2 (de) Die Mitose von Astrozyten von Tumorzellen des Nervensystems hemmende Oligosacharide und ein Verfahren zu ihrer Herstellung
DE68911049T2 (de) Therapeutische Verwendung des Isopropylesterderivates von Monosialogangliosiden bei Erkrankungen des Nervensystems, begleitet von Entzündungen.
DE69724156T2 (de) Aus mycobacterium tuberculosis extrahierter kohlenwasserstoffkomplex und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8131 Rejection